Foamix Pharmaceuticals Ltd., of Rehovot, Israel, said it set terms for its initial public offering, planning to raise $65 million from the sale of 6 million shares at a price range of $10 to $12 to help fund phase III studies of its lead product candidates, FMX101 for moderate to severe acne and FMX102 for common skin infection impetigo.